@article{TEXTUAL,
      recid = {10695},
      author = {Lee, UnJin and Frankenberger, Casey and Yun, Jieun and  Bevilacqua, Elena and Caldas, Carlos and Chin, Suet-Feung  and Rueda, Oscar M. and Reinitz, John and Rosner, Marsha  Rich},
      title = {A Prognostic Gene Signature for Metastasis-Free Survival  of Triple Negative Breast Cancer Patients},
      journal = {PLOS ONE},
      address = {2013-12-11},
      number = {TEXTUAL},
      abstract = {<p>Although triple negative breast cancers (TNBC) are the  most aggressive subtype of breast cancer, they currently  lack targeted therapies. Because this classification still  includes a heterogeneous collection of tumors, new tools to  classify TNBCs are urgently required in order to improve  our prognostic capability for high risk patients and  predict response to therapy. We previously defined a gene  expression signature, RKIP Pathway Metastasis Signature  (RPMS), based upon a metastasis-suppressive signaling  pathway initiated by Raf Kinase Inhibitory Protein (RKIP).  We have now generated a new BACH1 Pathway Metastasis gene  signature (BPMS) that utilizes targets of the metastasis  regulator BACH1. Specifically, we substituted  experimentally validated target genes to generate a new  BACH1 metagene, developed an approach to optimize patient  tumor stratification, and reduced the number of signature  genes to 30. The BPMS significantly and selectively  stratified metastasis-free survival in basal-like and, in  particular, TNBC patients. In addition, the BPMS further  stratified patients identified as having a good or poor  prognosis by other signatures including the Mammaprint® and  Oncotype® clinical tests. The BPMS is thus complementary to  existing signatures and is a prognostic tool for high risk  ER-HER2- patients. We also demonstrate the potential  clinical applicability of the BPMS as a single sample  predictor. Together, these results reveal the potential of  this pathway-based BPMS gene signature to identify high  risk TNBC patients that can respond effectively to targeted  therapy, and highlight BPMS genes as novel drug targets for  therapeutic development.</p>},
      url = {http://knowledge.uchicago.edu/record/10695},
}